… and cediranib in relapsed platinum-sensitive HGSOC or endometrioid ovarian cancer, a PFS
… (NCT02446600) comparing patients with platinum sensitive recurrent high-grade serous or …

… are one of new personalized treatments for patients with high-grade serous ovarian
cancer and demonstrate a high survival advantage in several randomized controlled trials (RCTs) …

… therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned …
Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. …

… Indeed, around 50% of all high-grade serous ovarian tumours are estimated to have a
deficiency in the homologous recombination (HR) DNA repair mechanism, with about 15% of …

… of high-grade serous ovarian cancers (including fallopian tube and primary peritoneal cancers…
. A phase I-II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1/2 …

… with RAD51C promotor methylation identified in ARIEL2 Part 1, a phase II study of the
PARPi rucaparib in patients with platinum-sensitive relapsed ovarian cancer (16). Of four cases …

… of PARP inhibitors. The current work reviews the leading clinical trials … PARP inhibitors (as
maintenance for newly diagnosed advanced and platinum-sensitive relapsed ovarian cancer), …

… and platinum-sensitive recurrent ovarian cancer. Poly (ADP-ribose) polymerase inhibitors
(PARP inhibitors… histology found in ovarian cancer is, high-grade serous ovarian cancer, given …

… Olaparib, the first PARP inhibitor to be granted approval, is currently indicated as … for patients
with relapsing high-grade, platinum-sensitive ovarian cancer that take into account BRCA …

… have been approved by the FDA and the European Medicines Agency for treatment of patients
with platinum-sensitive, recurrent HGSOC with or without loss of BRCA1/2 [20, 22, 23, 52–…